Literature DB >> 17478369

Feasibility of the Maylard transverse incision for ovarian cancer cytoreductive surgery.

James Fanning1, Allison Pruett, Robert F Flora.   

Abstract

The vast majority of abdominal incisions used in gynecologic surgery are either transverse or vertical midline. The advantages of a vertical midline incision are considered to be rapid abdominal entry and increased exposure to the abdomen and pelvis. The advantages of transverse incisions are purported to be cosmesis, decreased postoperative pain, decreased hernia rate, decreased abdominal adhesions, and fewer postoperative pulmonary complications. The Maylard incision is a transverse incision that combines the advantages of a transverse incision with improved pelvic and abdominal exposure. We wanted to evaluate the feasibility of the Maylard incision to provide adequate abdominal and pelvic exposure in women with advanced ovarian cancer undergoing cytoreductive surgery and to evaluate the extent of anterior abdominal wall adhesions at secondary cytoreductive surgery. In our experience, it appears that the Maylard incision provides adequate exposure to perform ovarian cytoreductive surgery. It appears that there are minimal anterior abdominal adhesions after cytoreductive surgery through a Maylard incision.

Entities:  

Mesh:

Year:  2007        PMID: 17478369     DOI: 10.1016/j.jmig.2006.11.009

Source DB:  PubMed          Journal:  J Minim Invasive Gynecol        ISSN: 1553-4650            Impact factor:   4.137


  2 in total

1.  Laparoscopic cytoreduction for primary advanced ovarian cancer.

Authors:  James Fanning; Rod Hojat; Jil Johnson; Bradford Fenton
Journal:  JSLS       Date:  2010 Jan-Mar       Impact factor: 2.172

2.  A novel robotic right colectomy for colon cancer via the suprapubic approach using the da Vinci Xi system: initial clinical experience.

Authors:  Hee Jae Lee; Gyu-Seog Choi; Jun Seok Park; Soo Yeun Park; Hye Jin Kim; In Teak Woo; In Kyu Park
Journal:  Ann Surg Treat Res       Date:  2018-01-30       Impact factor: 1.859

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.